Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
Sanofi has announced a new collaboration with Chicago-based EVOQ Therapeutics, potentially worth up to $500 million, to develop novel treatments for autoimmune diseases. The partnership, revealed on Thursday, centers around EVOQ's proprietary NanoDisc technology, which aims to restore the body's natural immune tolerance.
The pharmaceutical industry is witnessing another significant leadership change at the U.S. Food and Drug Administration (FDA), as Sandra Retzky, the director of the Office of Orphan Products Development, has been reassigned from her position. This move comes amid a series of high-profile departures from the FDA and other health agencies, as well as important policy developments affecting orphan drugs and rare disease treatments.
Connecticut-based biotech Veradermics has raised $150 million in an oversubscribed Series C funding round, marking a significant development in the pattern hair loss treatment landscape. The financing, led by SR One, will support the company's ongoing Phase III studies for its lead program VDPHL01, an extended-release oral formulation of minoxidil.
Novartis has reported significant progress in its efforts to treat IgA nephropathy (IgAN), a rare kidney disease, with positive final results from a Phase 3 trial of its drug Fabhalta. The Swiss pharmaceutical giant is now poised to seek full regulatory approval, potentially strengthening its position in an increasingly competitive market for IgAN treatments.
Adcytherix, a French antibody-drug conjugate (ADC) specialist, has successfully closed a €105 million ($122 million) Series A funding round, marking a significant milestone in the company's journey to advance its lead candidate into clinical trials. The Marseille-based biotech plans to leverage this substantial investment to file regulatory applications in multiple countries by year-end and expand its ADC pipeline.
Dianthus Therapeutics has entered into a licensing agreement with Nanjing Leads Biolabs for DNTH212, a novel bispecific antibody targeting autoimmune disorders. The deal, potentially worth up to $1 billion, marks a significant development in the pursuit of innovative treatments for conditions such as Sjögren's syndrome and systemic lupus erythematosus (SLE).
Merck & Co.'s blockbuster cancer immunotherapy Keytruda (pembrolizumab) has demonstrated a significant overall survival (OS) benefit in patients with platinum-resistant recurrent ovarian cancer, marking a potential breakthrough in the treatment of this challenging disease.
In a significant development for the healthcare industry, CommonSpirit Health's Trinity Health System and UPMC have announced their intention to pursue integration. This move, confirmed by both parties through a non-binding letter of intent, could reshape the healthcare landscape in Ohio and beyond.
Vega Health, a new startup founded by physician Mark Sendak, M.D., has emerged from stealth mode with a mission to transform how health systems acquire and monitor artificial intelligence (AI) solutions. Launched with $4 million in seed funding from Bessemer Venture Partners, Vega Health aims to address critical challenges in the healthcare AI ecosystem.
The pharmaceutical industry is experiencing a significant wave of restructuring, with major companies announcing substantial layoffs and organizational changes in the third quarter of 2025. According to recent data compiled by BioSpace, Q3 saw a staggering 280% year-over-year increase in layoffs, affecting over 23,000 employees across the sector.
AstraZeneca has announced a new collaboration with artificial intelligence company Immunai, valued at up to $85 million, to advance the discovery of a novel inflammatory bowel disease (IBD) therapy target. This partnership marks a significant step forward in the application of AI and machine learning to drug discovery in the pharmaceutical industry.
In a rapidly evolving landscape of mRNA therapeutics, researchers and industry leaders are pushing the boundaries of what's possible with this revolutionary technology. A recent webinar hosted by Biospace brought together experts from Officinae Bio, TriLink BioTechnologies, and Sartorius Polyplus to discuss cutting-edge advancements in mRNA design, optimization, and delivery methods.
